Condition: PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor · Sponsor: Relay Therapeutics, Inc.
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
This description comes directly from the study's public registry record.
Relay Therapeutics, Inc · 617-322-0731 · ClinicalTrials@relaytx.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| Beverly Hills Cancer Center | Beverly Hills, California, United States | Recruiting |
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Stanford Women's Cancer Center | Palo Alto, California, United States | Recruiting |
| University of California, Davis Comprehensive Cancer Center | Sacramento, California, United States | Recruiting |
| University of California San Diego Moores Cancer Center | San Diego, California, United States | Recruiting |
| University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Kaiser Permanente Medical Center | Vallejo, California, United States | Recruiting |
| Rocky Mountain Cancer Centers, LLP | Longmont, Colorado, United States | Recruiting |
| Yale-New Haven Hospital-Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Medical Oncology Hematology Consultants, P.A. | Newark, Delaware, United States | Recruiting |
+ 199 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06982521